Erasca Q4 net loss narrows as expenses fall

Overview

• U.S. oncology drug developer's Q4 net loss narrowed from prior year as expenses declined

• Company completed $259 mln upsized financing in January, boosting cash to fund operations into H2 2028

• Erasca reported promising early clinical data for ERAS-0015 and expanded licensing agreement to China, Hong Kong, Macau

Outlook

• Erasca expects Phase 1 monotherapy data for ERAS-0015 in H1 2026

• Company expects Phase 1 monotherapy data for ERAS-4001 in H2 2026

• Erasca expects current cash to fund operations into H2 2028

Result Drivers

• CLINICAL PROGRESS - Co cited promising early clinical activity for ERAS-0015, including ongoing partial responses in multiple RAS-mutant tumor types and favorable safety and pharmacokinetics data

• LOWER R&D COSTS - R&D expenses fell due to decreased spending on clinical trials, preclinical studies, discovery activities, outsourced services, and consulting fees

• LICENSING EXPANSION - Co expanded licensing agreement for ERAS-0015 to include China, Hong Kong, and Macau, securing worldwide rights

Company press release: ID:nGNX6ptlWt

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Erasca Inc is $11.50, about 25.8% below its March 11 closing price of $15.50

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.